Overview
TRANSTHERA-B (2617)
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, infla...
- Open
- 7.800
- High
- 7.800
- Low
- 7.220
- Prev. Close
- 7.575
- Volume
- 2.10M
- Turnover
- 15.54M
- Avg Price
- 7.397
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 7.66%
- 52wk High
- 221.400
- Volume Ratio
- 0.21
- Turnover Ratio
- 0.67%
- 52wk Low
- 7.220
- HK Mkt Cap
- 2.27B
- Market CapHKD
- 2.96B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.758
- EPSDynamic
- -0.539
- EPSStatic
- --
- BVPS
- 2.48
- P/B
- 2.93
- HK Shares
- 312.43M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 407.66M
- Min lot size
- 500
- Currency
- HKD
TRANSTHERA-B Analyst Rating
View moreForecast & Rating
Jul 9, 2026Daily Events
- Nov, 13
TransThera (2617.HK) spiked then faded to close down 4.95% at HK$7.58, having touched HK$8.055 in the morning session and HK$7.570 in the afternoon on 2.62 million shares worth about HK$20.28 million and a thin 0.84% turnover rate, as approval to convert 44,971,128 domestic unlisted shares into H shares, with the CSRC filing completed, stoked share-count expansion concerns in an already shallow book. Q2 2026 revenue was HK$20.48 million with a net loss of HK$55.13 million, narrowing 18.1% year on year, and a loss per share of HK$0.1373, while lead asset Tinengotinib remains at the registration-stage clinical phase and the national rollout of cholangiocarcinoma drug Yochanra has yet to convert into revenue. The stock is down 93.3% year to date, 96.92% below its 52-week high of HK$246, just 0.66% above its 52-week low of HK$7.53, and trades under both its MA20 of HK$8.40 and MA60 of HK$9.50. Though repeated share buyback disclosures on the HKEX may offer some cushion.
- Nov, 5
Led by a run of share buybacks and a 98-point gain in the Hong Kong market, Transthera-B opened higher and finished at HK$8.345, up 5.2% from the previous close of HK$7.930, after touching an intraday high of HK$8.400 from a HK$7.995 low and easing only modestly in the afternoon session. The company repurchased 56,500 shares for HK$454,600 on November 2, after 32,500 shares for HK$280,300 on October 27 and 52,500 shares for HK$467,000 on October 26, while the HKEX approved the conversion of 44,971,128 non-listed shares into H shares, about 11% of equity, keeping potential supply in focus. Q2 revenue was HK$20.48 million and net loss HK$55.13 million, narrowing 18.1% year on year, with EPS of -HK$0.1373, PE at -11x and PB at 3.37x, on a market capitalization of about HK$3.40 billion and a 1.92% turnover rate; total volume was 5.99 million shares with daily turnover of HK$49.4 million. The stock remains below its 20-day moving average of HK$8.923 and 60-day average of HK$9.735, down 92.63% year to date and 96.61% below its 52-week high of HK$246, though buybacks offer some support to the stock.
- Nov, 3
TransThera-B (2617.HK) reversed intraday gains to close down 1.1% at HK$7.81, as the HKEX approval to list 44,971,128 unlisted domestic shares converted into H shares, about 11% of equity, kept dilution concerns alive after the stock fell 6% in the prior session on the same news. The session traced a high of HK$8.455 in the morning and a low of HK$7.755 in the afternoon, with turnover of 5.61 million shares worth HK$45.22 million. The close sits only 3.72% above the 52-week low of HK$7.53, down 93.1% year to date and 96.83% below the 52-week high of HK$246, while remaining under the 20-day MA of HK$9.12 and 60-day MA of HK$9.824. For Q2, revenue was HK$20.48 million and net loss HK$55.13 million, with the loss narrowing 18.1% year on year and EPS improving 22.04% to -HK$0.1373; negative PE, 3.15x PB and ROE of -21.75% indicate profitability has not turned positive. The company bought back 56,500 shares for HK$454,600 on November 2, though the amount remains small relative to the 11% conversion.
- Oct, 27
TransThera Sciences fell 4.34% to HK$8.480 from HK$8.865, opening up at HK$8.980 before sliding through the morning to an afternoon low of HK$8.430, after the CSRC accepted its filing to convert 44,971,128 domestic shares into H shares, feeding expectations of a larger free float. Partial offset came from buybacks on October 22 to 26 totaling 110,500 shares for about HK$973,000, plus Jientai®, whose first clinical prescriptions were issued across multiple provinces with nationwide DTP pharmacy stocking, and the rollout of Yochanra, China's first domestically developed cholangiocarcinoma drug. Q2 2026 revenue was HK$20.48 million with a net loss of HK$55.13 million, narrowing 18.1% year on year. The stock is down 92.51% year to date, trades below its MA20 of HK$9.648 and MA60 of HK$10.069, and sits just 1.56% above its 52-week low of HK$8.35 against a HK$246 high. Though losses persist, a 3.42x PB leaves little earnings anchor.
- Oct, 23
TransThera-B (2617.HK) rebounded off its session low on Thursday: it dipped to HK$8.35 at 09:38 BJ, recovered to HK$8.945 by 11:22, and closed at HK$8.805, up 3.10% from the HK$8.54 prior close, on 3.363m shares worth roughly HK$29.4m. The move followed first clinical prescriptions for Jientai (Yochanra), China's first homegrown cholangiocarcinoma drug, in multiple provinces alongside nationwide DTP pharmacy stocking, plus a HK$47,200 repurchase of 5,500 shares on Oct 22. Fundamentals remain loss-making: Q2 revenue of about HK$20.5m and a net loss of HK$55.1m, 18.1% narrower YoY, with EPS at -HK$0.1373. The shares set a 52-week low of HK$8.35 yesterday, are down 92.22% YTD, sit 96.42% below the HK$246 peak, and remain under the MA20 of HK$9.799 and MA60 of HK$10.109. Though the buyback is small and rollout cadence is unproven.
News
Market Movers · Transthera hits record low
Weekly Review · Weekly Recap | TRANSTHERA-B -5.78%, late-week drop below HK$8
Weekly Review · Weekly Recap | TRANSTHERA-B +2.34%, share conversion approval stirs volatility
Market Movers · TransThera climbs 6%
Market Movers · Transthera drops 6% on approval to convert unlisted shares to H shares
PUBT · TransThera Wins Approval to Convert 44,971,128 Unlisted Shares Into H Shares
